- Home
- BYSI vs INO Comparison
BYSI vs INO Comparison
Compare BYSI & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- INO
- Stock Information
- Founded
- BYSI 2010
- INO 1979
- Country
- BYSI United States
- INO United States
- Employees
- BYSI N/A
- INO N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- INO Medical/Dental Instruments
- Sector
- BYSI Health Care
- INO Health Care
- Exchange
- BYSI Nasdaq
- INO Nasdaq
- Market Cap
- BYSI 69.3M
- INO 75.4M
- IPO Year
- BYSI 2017
- INO 1998
- Fundamental
- Price
- BYSI $1.72
- INO $2.08
- Analyst Decision
- BYSI
- INO Buy
- Analyst Count
- BYSI 0
- INO 6
- Target Price
- BYSI N/A
- INO $17.00
- AVG Volume (30 Days)
- BYSI 21.8K
- INO 1.2M
- Earning Date
- BYSI 01-01-0001
- INO 03-05-2025
- Dividend Yield
- BYSI N/A
- INO N/A
- EPS Growth
- BYSI N/A
- INO N/A
- EPS
- BYSI N/A
- INO N/A
- Revenue
- BYSI $1,876,000.00
- INO $203,413.00
- Revenue This Year
- BYSI N/A
- INO N/A
- Revenue Next Year
- BYSI N/A
- INO $2,290.97
- P/E Ratio
- BYSI N/A
- INO N/A
- Revenue Growth
- BYSI 21.03
- INO N/A
- 52 Week Low
- BYSI $0.82
- INO $1.74
- 52 Week High
- BYSI $4.00
- INO $14.75
- Technical
- Relative Strength Index (RSI)
- BYSI 52.47
- INO 39.63
- Support Level
- BYSI $1.58
- INO $1.83
- Resistance Level
- BYSI $1.75
- INO $2.39
- Average True Range (ATR)
- BYSI 0.09
- INO 0.17
- MACD
- BYSI 0.02
- INO 0.11
- Stochastic Oscillator
- BYSI 74.07
- INO 51.56
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.